RNAi Therapeutics Market (2nd Edition), 2019-2030

CABOT, Ark. - April 10, 2020 - PRLog -- Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

Key Market Insights

Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.

More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.

Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (60%).

The USD 10 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):

• Amotz Shemi (Chief Executive Officer, Silenseed (http://silenseed.com/))

The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

or email sales@rootsanalysis.com (mailto:sales@rootsanalysis.com?subject=RNAi%20Therapeutics%20Market%20(2nd%20Edition)%2C%202019-2030%20-%20Press%20Release%20Query)
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com (mailto:Gaurav.Chaudhary@rootsanalysis.com?subject=RNAi%20Therapeutics%20Market%20(2nd%20Edition)%2C%202019-2030%20-%20Press%20Release%20Query)